AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22846446 — intervention group
Group type: COMPARATOR
Intervention: Obituary specifying drug overdose as the cause of death
Number of subjects: 253
Study 21771948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric Constraint‐Induced Movement therapy
Number of subjects: 20
Study 21771948 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 20
Study 19917453 — intervention group
Group type: EXPERIMENTAL
Intervention: Low saturated fat (LSF) diet with 25 g of soy protein and 15 g of soluble fiber daily for 2 months
Number of subjects: 43
Study 16504873 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-session treatment (instrumentation and root-filling)
Number of subjects: 256
Study 16504873 — intervention group
Group type: COMPARATOR
Intervention: 2-session treatment (calcium hydroxide as an intracanal dressing)
Number of subjects: 256
Study 16504873 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative pain recorded 1 week after permanent filling
Number of subjects: 256
Study 16504873 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of overfilling
Number of subjects: 256
Study 12736112 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5‐FU (300 mg/m(2)/day for a maximum of 24 weeks)
Number of subjects: 88
Study 12736112 — intervention group
Group type: COMPARATOR
Intervention: PVI 5‐FU (300 mg/m(2)/day for a maximum of 24 weeks) + MMC (7 mg/m(2) 6 weekly for four courses)
Number of subjects: 88
Study 12736112 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5‐FU
Number of subjects: 88
Study 12736112 — intervention group
Group type: COMPARATOR
Intervention: PVI 5‐FU + MMC
Number of subjects: 88
Study 12736112 — intervention group
Group type: EXPERIMENTAL
Intervention: PVI 5‐FU and PVI 5‐FU + MMC
Number of subjects: 88
Study 11110155 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioactive glass (S93P4)
Number of subjects: 28
Study 11110155 — intervention group
Group type: COMPARATOR
Intervention: Autogenous cartilage implants
Number of subjects: 28
Study 9418699 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic laser surgery
Number of subjects: 63
Study 9418699 — intervention group
Group type: COMPARATOR
Intervention: Control group (symptomatic controls)
Number of subjects: 63
Study 8500376 — intervention group
Group type: EXPERIMENTAL
Intervention: Diathermy hemorrhoidectomy
Number of subjects: 20
Study 8500376 — intervention group
Group type: COMPARATOR
Intervention: Scissor dissection Milligan‐Morgan hemorrhoidectomy
Number of subjects: 20
Study 3367452 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 71
Study 3367452 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 3367452 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine and Placebo
Number of subjects: 71
Study 31363810 — intervention group
Group type: EXPERIMENTAL
Intervention: Transillumination (TL) technique used on one side of the face
Number of subjects: 72
Study 31363810 — intervention group
Group type: COMPARATOR
Intervention: No vascular exploration method used on the other side of the face
Number of subjects: 72
Study 29680809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (loading dose 0.6 µg/kg administered 10 min before anaesthesia induction, followed by continuous infusion at 0.5 µg/kg/hour until 1 hour before the end of surgery)
Number of subjects: 620
Study 29680809 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (administered with an identical rate as in the dexmedetomidine group)
Number of subjects: 620
Study 29680809 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 620
Study 28790165 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR
Number of subjects: 639
Study 28790165 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-PCI FFR of 0.92
Number of subjects: 639
Study 25708655 — intervention group
Group type: EXPERIMENTAL
Intervention: Telepsychiatry (TP) testing
Number of subjects: 22
Study 25708655 — intervention group
Group type: COMPARATOR
Intervention: In-person (IP) testing
Number of subjects: 22
Study 24093809 — intervention group
Group type: EXPERIMENTAL
Intervention: FTC/TDF pre-exposure prophylaxis (PrEP)
Number of subjects: 52
Study 21436688 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorneal ring (group 1)
Number of subjects: 20
Study 21436688 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 2)
Number of subjects: 20
Study 18361082 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Adolescent Smoking Cessation Program (CASCP) - 4 sessions of 30 minutes each
Number of subjects: 121
Study 18361082 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Adolescent Smoking Cessation Program (CASCP)
Number of subjects: 121
Study 18361082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 121
Study 21829106 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25-50 mg/day)
Number of subjects: 138
Study 21829106 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 138
Study 21829106 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (25-50 mg/day) and Escitalopram (10-20 mg/day)
Number of subjects: 138
Study 16060253 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of carotid artery stenting (CAS) and carotid endarterectomy (CEA)
Number of subjects: 18
Study 16060253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral CEA
Number of subjects: 18
Study 16060253 — intervention group
Group type: EXPERIMENTAL
Intervention: CAS then CEA of contra-lateral symptomatic side
Number of subjects: 18
Study 16060253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral CAS
Number of subjects: 18
Study 12779247 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% date palm kernel cream applied twice a day for 5 weeks
Number of subjects: 10
Study 12779247 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream applied twice a day for 5 weeks
Number of subjects: 10
Study 9440580 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 240
Study 9440580 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 240
Study 8046315 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pulse-wave amplitude (<5 mm) during reactive hyperaemia
Number of subjects: 636
Study 8046315 — intervention group
Group type: COMPARATOR
Intervention: Other plethysmographically recorded variables
Number of subjects: 636
Study 2646995 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray (BDP‐AQ) 42 micrograms/spray, 1 spray in each nostril twice daily
Number of subjects: 101
Study 2646995 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray, identical to BDP‐AQ
Number of subjects: 101
Study 28643058 — intervention group
Group type: EXPERIMENTAL
Intervention: FloShield Air System®
Number of subjects: 104
Study 28643058 — intervention group
Group type: COMPARATOR
Intervention: water + PVI solution
Number of subjects: 104
Study 28077751 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic algorithm on a smartphone
Number of subjects: 504
Study 28077751 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper algorithm
Number of subjects: 504
Study 28077751 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 504
Study 25659348 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS‐MPH
Number of subjects: 255
Study 25659348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study 23404353 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic treatment (Bioclavid) for 100 days
Number of subjects: 162
Study 23404353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 21926373 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 75
Study 21926373 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.25%
Number of subjects: 75
Study 18205945 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus amodiaquine as a single daily intake
Number of subjects: 316
Study 18205945 — intervention group
Group type: COMPARATOR
Intervention: Artesunate plus amodiaquine as two daily intakes
Number of subjects: 316
Study 18205945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 316
Study 16801658 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiologic testing including facial nerve conduction studies, needle electromyography examination of facial muscles, and recording of the blink reflex and trigeminofacial inhibitory reflex.
Number of subjects: 24
Study 16801658 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurophysiologic testing results.
Number of subjects: 24
Study 16801658 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigeminal facial reflexes assessment.
Number of subjects: 24
Study 15023669 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements (MR)
Number of subjects: 55
Study 15023669 — intervention group
Group type: COMPARATOR
Intervention: Structured low fat diet (C)
Number of subjects: 55
Study 11145798 — intervention group
Group type: EXPERIMENTAL
Intervention: MFMA spinal manipulative therapy (SMT)
Number of subjects: 40
Study 11145798 — intervention group
Group type: COMPARATOR
Intervention: Sham-SMT
Number of subjects: 40
Study 11145798 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 8792879 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30
Study 8792879 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 30
Study 8792879 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 30
Study 1621668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (7.5 or 10 mg/kg)
Number of subjects: 37
Study 1621668 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (10 mg/kg)
Number of subjects: 37
Study 1621668 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 6719656 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg glucagon intravenously
Number of subjects: 51
Study 6719656 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 29242349 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 40 μg/day
Number of subjects: 460
Study 29242349 — intervention group
Group type: EXPERIMENTAL
Intervention: ITCA 650 60 μg/day
Number of subjects: 460
Study 29242349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 460
Study 27188979 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (150 mg/day)
Number of subjects: 17
Study 27188979 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 24576720 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electric acupoint stimulation (TEAS)
Number of subjects: 60
Study 24576720 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 60
Study 24119521 — intervention group
Group type: EXPERIMENTAL
Intervention: DS+bFGF paste
Number of subjects: 129
Study 24119521 — intervention group
Group type: COMPARATOR
Intervention: Vehicle only
Number of subjects: 129
Study 24119521 — intervention group
Group type: COMPARATOR
Intervention: DS alone
Number of subjects: 129
Study 24119521 — intervention group
Group type: COMPARATOR
Intervention: bFGF alone
Number of subjects: 129
Study 20961384 — intervention group
Group type: EXPERIMENTAL
Intervention: Profit‐Haije‐Brush (PHB)
Number of subjects: 36
Study 20961384 — intervention group
Group type: COMPARATOR
Intervention: Control flat‐trimmed manual reference toothbrush (ADA)
Number of subjects: 36
Study 18781288 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day)
Number of subjects: 90
Study 18781288 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid (5 mg/day) and methylcobalamin (500 microg/day; intramuscularly)
Number of subjects: 90
Study 18781288 — intervention group
Group type: COMPARATOR
Intervention: No vitamin supplementation
Number of subjects: 90
Study 16636750 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat (MT), 10 mg orally twice daily until tumor progression
Number of subjects: 162
Study 16636750 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PB)
Number of subjects: 162
Study 16636750 — intervention group
Group type: EXPERIMENTAL
Intervention: Marimastat (MT)
Number of subjects: 162
Study 15755199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory care
Number of subjects: 26
Study 15755199 — intervention group
Group type: COMPARATOR
Intervention: In-patient care
Number of subjects: 26
Study 11728983 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysis patients
Number of subjects: 19
Study 11728983 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP levels (> 16.8 mg/L) in dialysis patients
Number of subjects: 19
Study 11728983 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP values
Number of subjects: 19
Study 9009110 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g lactulose
Number of subjects: 8
Study 9009110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8235922 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg twice a day for 7 days
Number of subjects: 27
Study 8235922 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole 500 mg twice a day for 7 days
Number of subjects: 27
Study 3319147 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF) derived from leukocytes of the patients' husbands
Number of subjects: 60
Study 3319147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 3319147 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer factor (TF)
Number of subjects: 60
Study 29864682 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 polyunsaturated fatty acids (PUFA) supplementation (2 g for 6 months)
Number of subjects: 20
Study 26601728 — intervention group
Group type: EXPERIMENTAL
Intervention: VLO Immediate (GIVLO)
Number of subjects: 46
Study 26601728 — intervention group
Group type: EXPERIMENTAL
Intervention: VLO Longitudinal (GLVLO)
Number of subjects: 46
Study 26601728 — intervention group
Group type: COMPARATOR
Intervention: Control group (GIC)
Number of subjects: 46
Study 26601728 — intervention group
Group type: COMPARATOR
Intervention: Control group (GLC)
Number of subjects: 46
Study 25689364 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care nurse-delivered walking intervention with 4 consultations over 3 months
Number of subjects: 298
Study 25689364 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 298
Study 25689364 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care nurse-delivered walking intervention
Number of subjects: 298
Study 23786174 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening participants after obtaining PSA result
Number of subjects: 2100
Study 23786174 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening participants after DRE
Number of subjects: 2100
Study 23786174 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening participants
Number of subjects: 2100
Study 20620377 — intervention group
Group type: EXPERIMENTAL
Intervention: BioGlue
Number of subjects: 102
Study 20620377 — intervention group
Group type: COMPARATOR
Intervention: Vivostat
Number of subjects: 102
Study 18391156 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral STN-DBS
Number of subjects: 12
Study 18391156 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 male subjects free of neurologic deficits)
Number of subjects: 12
Study 16507193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine 1,000 microg (early adenosine group)
Number of subjects: 90
Study 16507193 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal adenosine 1,000 microg (late adenosine group)
Number of subjects: 90
Study 16507193 — intervention group
Group type: COMPARATOR
Intervention: Control group (no test drug)
Number of subjects: 90
Study 14714812 — intervention group
Group type: EXPERIMENTAL
Intervention: Huggins pitch
Number of subjects: 0
Study 14714812 — intervention group
Group type: EXPERIMENTAL
Intervention: Binaural coherence edge pitch
Number of subjects: 0
Study 14714812 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10074976 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia
Number of subjects: 102
Study 10074976 — intervention group
Group type: COMPARATOR
Intervention: No spinal anesthesia
Number of subjects: 102
Study 8647722 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperthermia (average temperature of 38.4 degrees C)
Number of subjects: 0
Study 2404514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream applied once daily for 12 weeks
Number of subjects: 20
Study 2404514 — intervention group
Group type: COMPARATOR
Intervention: Placebo applied once daily for 12 weeks
Number of subjects: 20
Study 2404514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin cream
Number of subjects: 20
Study 6996627 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine, 1 mg twice daily p.o.
Number of subjects: 30
Study 6996627 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa, 250 mg three times a day p.o.
Number of subjects: 30
Study 29486750 — intervention group
Group type: EXPERIMENTAL
Intervention: Game-based exercise training program
Number of subjects: 112
Study 29486750 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 112
Study 26643326 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir (NS3/4A inhibitor boosted with ritonavir) and Ombitasvir (NS5A inhibitor)
Number of subjects: 436
Study 26643326 — intervention group
Group type: EXPERIMENTAL
Intervention: Paritaprevir and Ombitasvir
Number of subjects: 436
Study 24676506 — intervention group
Group type: EXPERIMENTAL
Intervention: TEO (high-definition 2-D transanal endoscopic operation)
Number of subjects: 34
Study 24676506 — intervention group
Group type: COMPARATOR
Intervention: TEM (transanal endoscopic microsurgery)
Number of subjects: 34
Study 23467861 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL epidural injection of 0.1% ropivacaine
Number of subjects: 66
Study 23467861 — intervention group
Group type: COMPARATOR
Intervention: 10 mL of 0.9% saline solution (control)
Number of subjects: 66
Study 23467861 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 66
Study 20414043 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (CT) 20 mg iv over 120 min
Number of subjects: 36
Study 20414043 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline iv over 120 min)
Number of subjects: 36
Study 19105013 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program delivered by a lay health advisor
Number of subjects: 851
Study 19105013 — intervention group
Group type: COMPARATOR
Intervention: Physician letter and brochure about cervical cancer screening (control group)
Number of subjects: 851
Study 16831654 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polylactide pins
Number of subjects: 164
Study 16831654 — intervention group
Group type: COMPARATOR
Intervention: Standard metal mini-fragment implants
Number of subjects: 164
Study 16831654 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment methods
Number of subjects: 164
Study 12796070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once-daily subcutaneous injection for 19 to 23 days
Number of subjects: 656
Study 12796070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 656
Study 12796070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 656
Study 10229588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratympanic gentamicin infusion (26.7 mg/mL, 0.2 to 0.3 mL)
Number of subjects: 32
Study 8911453 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronidazole at a concentration of 5 mg/ml
Number of subjects: 0
Study 1663391 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar breads
Number of subjects: 0
Study 1663391 — intervention group
Group type: COMPARATOR
Intervention: Control breads
Number of subjects: 0
Study 6127965 — intervention group
Group type: EXPERIMENTAL
Intervention: 131-iodine (n = 16)
Number of subjects: 36
Study 6127965 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (n = 20)
Number of subjects: 36
Study 3925751 — intervention group
Group type: EXPERIMENTAL
Intervention: High zinc supplement
Number of subjects: 105
Study 3925751 — intervention group
Group type: COMPARATOR
Intervention: Different zinc supplement groups
Number of subjects: 105
Study 3925751 — intervention group
Group type: COMPARATOR
Intervention: Copper dose groups
Number of subjects: 105
Study 31118449 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency catheter ablation (RFCA)
Number of subjects: 210
Study 31118449 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 210
Study 31118449 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D mapping-guided cryoablation
Number of subjects: 210
Study 30045593 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (active treatment)
Number of subjects: 29
Study 30045593 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 29
Study 26817469 — intervention group
Group type: EXPERIMENTAL
Intervention: COX inhibitor (acetaminophen, 4 gram/day)
Number of subjects: 15
Study 26817469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 24671720 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) supplementation
Number of subjects: 45
Study 24671720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 22206630 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 25
Study 22206630 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 25
Study 20415341 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback actigraphy
Number of subjects: 0
Study 18581975 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) to common inhalant allergens
Number of subjects: 156
Study 18581975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE (asIgE) testing
Number of subjects: 156
Study 18581975 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen-specific IgE (asIgE) testing for food allergens
Number of subjects: 156